Angelo J. Trapani

3.4k total citations
74 papers, 1.6k citations indexed

About

Angelo J. Trapani is a scholar working on Cardiology and Cardiovascular Medicine, Oncology and Physiology. According to data from OpenAlex, Angelo J. Trapani has authored 74 papers receiving a total of 1.6k indexed citations (citations by other indexed papers that have themselves been cited), including 35 papers in Cardiology and Cardiovascular Medicine, 27 papers in Oncology and 26 papers in Physiology. Recurrent topics in Angelo J. Trapani's work include Peptidase Inhibition and Analysis (26 papers), Nitric Oxide and Endothelin Effects (25 papers) and Diabetes Treatment and Management (15 papers). Angelo J. Trapani is often cited by papers focused on Peptidase Inhibition and Analysis (26 papers), Nitric Oxide and Endothelin Effects (25 papers) and Diabetes Treatment and Management (15 papers). Angelo J. Trapani collaborates with scholars based in United States, Switzerland and Italy. Angelo J. Trapani's co-authors include Arco Y. Jeng, Stéphane De Lombaert, Martin Lefkowitz, Kam F. Fok, Gillian M. Olins, Paula Savage, Kerry L. Spear, Rajesh Ghai, Mark M. Knuepfer and Yumi Sakane and has published in prestigious journals such as Circulation, Journal of the American College of Cardiology and Circulation Research.

In The Last Decade

Angelo J. Trapani

73 papers receiving 1.5k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Angelo J. Trapani United States 23 661 525 448 325 254 74 1.6k
Robert L. Panek United States 22 534 0.8× 1.1k 2.2× 402 0.9× 225 0.7× 124 0.5× 51 1.8k
Wolfram Steinke Germany 15 487 0.7× 591 1.1× 582 1.3× 384 1.2× 154 0.6× 31 1.7k
Thomas W von Geldern United States 26 382 0.6× 617 1.2× 458 1.0× 240 0.7× 177 0.7× 57 2.1k
Rebecca S. Keller United States 19 597 0.9× 704 1.3× 147 0.3× 141 0.4× 161 0.6× 34 1.6k
Magdi M. Asaad United States 21 499 0.8× 411 0.8× 98 0.2× 185 0.6× 307 1.2× 45 1.1k
Jacques Mizrahi Switzerland 27 585 0.9× 1.5k 2.8× 541 1.2× 200 0.6× 158 0.6× 75 2.4k
William J. Chiou United States 23 254 0.4× 1.2k 2.4× 736 1.6× 360 1.1× 215 0.8× 57 2.2k
Thomas A. Morinelli United States 22 280 0.4× 755 1.4× 229 0.5× 251 0.8× 85 0.3× 57 1.6k
Yuying C. Hwang United States 24 194 0.3× 743 1.4× 177 0.4× 202 0.6× 234 0.9× 34 1.8k
Brian D. Dayton United States 22 211 0.3× 650 1.2× 463 1.0× 100 0.3× 114 0.4× 38 1.5k

Countries citing papers authored by Angelo J. Trapani

Since Specialization
Citations

This map shows the geographic impact of Angelo J. Trapani's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Angelo J. Trapani with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Angelo J. Trapani more than expected).

Fields of papers citing papers by Angelo J. Trapani

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Angelo J. Trapani. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Angelo J. Trapani. The network helps show where Angelo J. Trapani may publish in the future.

Co-authorship network of co-authors of Angelo J. Trapani

This figure shows the co-authorship network connecting the top 25 collaborators of Angelo J. Trapani. A scholar is included among the top collaborators of Angelo J. Trapani based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Angelo J. Trapani. Angelo J. Trapani is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Nester, Carla, Ute Eisenberger, Alexandre Karras, et al.. (2024). Iptacopan Reduces Proteinuria and Stabilizes Kidney Function in C3 Glomerulopathy. Kidney International Reports. 10(2). 432–446. 2 indexed citations
2.
Nester, Carla, Richard J. Smith, David Kavanagh, et al.. (2024). Efficacy and Safety of Iptacopan in Patients with C3 Glomerulopathy: 12-Month Results from the Phase 3 APPEAR-C3G Study. Journal of the American Society of Nephrology. 35(10S). 1 indexed citations
3.
Bomback, Andrew S., David Kavanagh, Marina Vivarelli, et al.. (2022). Alternative Complement Pathway Inhibition With Iptacopan for the Treatment of C3 Glomerulopathy-Study Design of the APPEAR-C3G Trial. Kidney International Reports. 7(10). 2150–2159. 39 indexed citations
4.
Trapani, Angelo J., et al.. (2004). CGS 35601 and its Orally Active Prodrug CGS 37808 as Triple Inhibitors of Endothelin-converting Enzyme-1, Neutral Endopeptidase 24.11, and Angiotensin-converting Enzyme. Journal of Cardiovascular Pharmacology. 44(Supplement 1). S211–S215. 10 indexed citations
5.
Trapani, Angelo J., Stéphane De Lombaert, Michael E. Beil, et al.. (2000). Cgs 34043. Life Sciences. 67(9). 1025–1033. 10 indexed citations
6.
Jeng, Arco Y., Stéphane De Lombaert, Michael E. Beil, et al.. (2000). Design and Synthesis of a Potent and Selective Endothelin-Converting Enzyme Inhibitor, CGS 35066. Journal of Cardiovascular Pharmacology. 36(Supplement 1). S36–S39. 19 indexed citations
7.
Trapani, Angelo J., Michael E. Beil, Charles W. Bruseo, Stéphane De Lombaert, & Arco Y. Jeng. (2000). Pharmacological Properties of CGS 35066, a Potent and Selective Endothelin-Converting Enzyme Inhibitor, in Conscious Rats. Journal of Cardiovascular Pharmacology. 36(Supplement 1). S40–S43. 17 indexed citations
8.
Lombaert, Stéphane De, et al.. (1996). Design and Pharmacology of Dual Angiotensin-Converting Enzyme and Neutral Endopeptidase Inhibitors. Current Pharmaceutical Design. 2(5). 443–462. 9 indexed citations
9.
Fink, Cynthia A., et al.. (1995). New .alpha.-Thiol Dipeptide Dual Inhibitors of Angiotensin-I-Converting Enzyme and Neutral Endopeptidase EC 3.4.24.11. Journal of Medicinal Chemistry. 38(26). 5023–5030. 18 indexed citations
10.
Trapani, Angelo J., et al.. (1995). Inhibition of Big ET-1-Induced Pressor Response by an Orally Active Dual Inhibitor of Endothelin-Converting Enzyme and Neutral Endopeptidase 24.11. Journal of Cardiovascular Pharmacology. 26. S69–71. 20 indexed citations
11.
Ksander, Gary M., et al.. (1995). Dicarboxylic Acid Dipeptide Neutral Endopeptidase Inhibitors. Journal of Medicinal Chemistry. 38(10). 1689–1700. 68 indexed citations
12.
Lombaert, Stéphane De, Mark D. Erion, Jenny Tan, et al.. (1994). N-Phosphonomethyl Dipeptides and Their Phosphonate Prodrugs, a New Generation of Neutral Endopeptidase (NEP, EC 3.4.24.11) Inhibitors. Journal of Medicinal Chemistry. 37(4). 498–511. 69 indexed citations
13.
Stanton, James L., et al.. (1993). Heterocyclic lactam derivatives as dual angiotensin converting enzyme and neutral endopeptidase 24.11 inhibitors. Journal of Medicinal Chemistry. 36(24). 3829–3833. 24 indexed citations
14.
Bovy, Philippe R., Gillian M. Olins, Ellen G. McMahon, et al.. (1990). Structure-activity relationships for the carboxy-terminus-truncated analogs of angiotensin II, a new class of angiotensin II antagonists. Journal of Medicinal Chemistry. 33(5). 1477–1482. 11 indexed citations
15.
Han, Song‐Ping, et al.. (1990). Cardiac and vascular actions of sarafotoxin S6b and endothelin-1. Life Sciences. 46(11). 767–775. 14 indexed citations
16.
Han, Song‐Ping, Mark M. Knuepfer, Angelo J. Trapani, Kam F. Fok, & Thomas C. Westfall. (1990). Endothelin and sarafotoxin S6b have similar vasoconstrictor effects and postsynaptically mediated mechanisms. European Journal of Pharmacology. 177(1-2). 29–34. 14 indexed citations
17.
Koepke, J P, Pramod P. Mehta, Gillian M. Olins, et al.. (1990). Atriopeptin Regulation and Renal Function in Conscious Spontaneously Hypertensive Rats. American Journal of Hypertension. 3(8_Pt_1). 622–627. 6 indexed citations
18.
McMahon, Ellen G., et al.. (1989). In vitro and in vivo activity of chymotrypsin-activated big endothelin (porcine 1–40). Biochemical and Biophysical Research Communications. 161(2). 406–413. 28 indexed citations
19.
Olins, Gillian M., Philip A. Krieter, Angelo J. Trapani, Kerry L. Spear, & Philippe R. Bovy. (1989). Specific inhibitors of endopeptidase 24.11 inhibit the metabolism of atrial natriuretic peptides in vitro and in vivo. Molecular and Cellular Endocrinology. 61(2). 201–208. 62 indexed citations
20.
Trapani, Angelo J., Kirk W. Barron, Diane K. Hartle, & Michael J. Brody. (1984). Participation of the median preoptic nucleus in hypertension produced by sinoaortic baroreceptor denervation (SAD). Federation Proceedings. 43(3). 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Robert L. Panek Breakdown of academic impact, for papers by Wolfram Steinke Breakdown of academic impact, for papers by Thomas W von Geldern Breakdown of academic impact, for papers by Rebecca S. Keller Breakdown of academic impact, for papers by Magdi M. Asaad Breakdown of academic impact, for papers by Jacques Mizrahi Breakdown of academic impact, for papers by William J. Chiou Breakdown of academic impact, for papers by Thomas A. Morinelli Breakdown of academic impact, for papers by Yuying C. Hwang Breakdown of academic impact, for papers by Brian D. Dayton
Rankless by CCL
2026